More about

Wet Age-Related Macular Degeneration

News
May 14, 2022
3 min watch
Save

VIDEO: OPT-302 enrolling for two phase 3 clinical trials

VIDEO: OPT-302 enrolling for two phase 3 clinical trials

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, David S. Boyer, MD, discusses the progress of two phase 3 clinical trials for OPT-302 in combination with either ranibizumab or aflibercept.

News
May 13, 2022
2 min watch
Save

VIDEO: Outlook Therapeutics updates intravitreal bevacizumab path toward commercialization

VIDEO: Outlook Therapeutics updates intravitreal bevacizumab path toward commercialization

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, chief operations officer for Outlook Therapeutics, discusses the latest update on ONS-5010 for the treatment of wet AMD.

News
May 12, 2022
2 min watch
Save

VIDEO: EyePoint shares 8- and 9-month data on wet AMD treatment

VIDEO: EyePoint shares 8- and 9-month data on wet AMD treatment

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901.

News
May 03, 2022
2 min watch
Save

VIDEO: Higher dose of aflibercept yields better visual acuity in wet AMD

VIDEO: Higher dose of aflibercept yields better visual acuity in wet AMD

DENVER — A higher 8 mg dose of aflibercept for the treatment of wet AMD resulted in patients having a two- or three-letter improvement in visual acuity vs. the traditional 2 mg dose, David Brown, MD, said here at ARVO.

News
May 02, 2022
1 min read
Save

High-dose aflibercept maintains visual acuity in wet AMD

High-dose aflibercept maintains visual acuity in wet AMD

DENVER — High-dose aflibercept maintained visual acuity in patients with neovascular age-related macular degeneration at 48 months, according to a study presented at the Association for Research in Vision and Ophthalmology meeting.

News
May 01, 2022
2 min watch
Save

VIDEO: OPT-302 with ranibizumab improved vision in patients with wet AMD

VIDEO: OPT-302 with ranibizumab improved vision in patients with wet AMD

DENVER — In this Healio Video Perspective from the ARVO meeting, Jason S. Slakter, MD, discusses his poster on phase 2b study results of OPT-302 (Opthea) in combination with ranibizumab for wet age-related macular degeneration.

News
April 24, 2022
1 min read
Save

Diet, genetics and family history play role in AMD progression

Diet, genetics and family history play role in AMD progression

WASHINGTON — Age-related macular degeneration has a significant impact on vision across the population, according to a speaker here.

News
April 01, 2022
1 min read
Save

European Commission approves Beovu for DME

The European Commission has granted approval to Beovu for the treatment of visual impairment caused by diabetic macular edema, according to a press release from Novartis.

News
March 21, 2022
10 min listen
Save

Dr. Mali's Top 5 Predictions in Ophthalmology for 2022

Dr. Mali's Top 5 Predictions in Ophthalmology for 2022

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

News
March 04, 2022
33 min listen
Save

The Latest News and Notes, plus Conversation with Eric Rosenberg, DO

The Latest News and Notes, plus Conversation with Eric Rosenberg, DO

In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eye care, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology.

View more